ES2262174T3 - Forma de dosificacion y procedimiento de administracion de medicamentos. - Google Patents
Forma de dosificacion y procedimiento de administracion de medicamentos.Info
- Publication number
- ES2262174T3 ES2262174T3 ES97910713T ES97910713T ES2262174T3 ES 2262174 T3 ES2262174 T3 ES 2262174T3 ES 97910713 T ES97910713 T ES 97910713T ES 97910713 T ES97910713 T ES 97910713T ES 2262174 T3 ES2262174 T3 ES 2262174T3
- Authority
- ES
- Spain
- Prior art keywords
- drug
- hours
- dose
- tolerance
- methylphenidate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 239000002552 dosage form Substances 0.000 title claims description 46
- 238000001647 drug administration Methods 0.000 title description 8
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims description 143
- 229940079593 drug Drugs 0.000 claims description 136
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 41
- 229960001344 methylphenidate Drugs 0.000 claims description 41
- 230000002459 sustained effect Effects 0.000 claims description 33
- 230000001154 acute effect Effects 0.000 claims description 20
- 230000007423 decrease Effects 0.000 claims description 16
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 13
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 10
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 8
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 8
- 230000006735 deficit Effects 0.000 claims description 7
- 238000011161 development Methods 0.000 claims description 7
- 229940025084 amphetamine Drugs 0.000 claims description 6
- 229960000632 dexamfetamine Drugs 0.000 claims description 6
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 6
- 229960001252 methamphetamine Drugs 0.000 claims description 6
- FRCFWPVMFJMNDP-UHFFFAOYSA-N n-propan-2-ylaniline Chemical compound CC(C)NC1=CC=CC=C1 FRCFWPVMFJMNDP-UHFFFAOYSA-N 0.000 claims description 6
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims description 6
- 229960000761 pemoline Drugs 0.000 claims description 6
- 230000033764 rhythmic process Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 208000013403 hyperactivity Diseases 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 49
- 230000001174 ascending effect Effects 0.000 description 23
- 238000013268 sustained release Methods 0.000 description 13
- 239000012730 sustained-release form Substances 0.000 description 13
- 210000003169 central nervous system Anatomy 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 10
- 230000006399 behavior Effects 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010052804 Drug tolerance Diseases 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 230000007012 clinical effect Effects 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 206010027374 Mental impairment Diseases 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000003368 psychostimulant agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 241001074085 Scophthalmus aquosus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 230000001660 hyperkinetic effect Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- DUGOZIWVEXMGBE-OLZOCXBDSA-N methyl (S)-phenyl[(R)-piperidin-2-yl]acetate Chemical compound C([C@@H]1[C@@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-OLZOCXBDSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2872696P | 1996-09-30 | 1996-09-30 | |
| US28726P | 1996-09-30 | ||
| US3051496P | 1996-11-12 | 1996-11-12 | |
| US30514P | 1996-11-12 | ||
| US4412197P | 1997-04-22 | 1997-04-22 | |
| US44121P | 1997-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2262174T3 true ES2262174T3 (es) | 2006-11-16 |
Family
ID=27363329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97910713T Expired - Lifetime ES2262174T3 (es) | 1996-09-30 | 1997-09-16 | Forma de dosificacion y procedimiento de administracion de medicamentos. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0932388B1 (https=) |
| JP (3) | JP4714313B2 (https=) |
| CN (1) | CN1231603A (https=) |
| AT (1) | ATE321529T1 (https=) |
| AU (1) | AU4801497A (https=) |
| CA (1) | CA2264852C (https=) |
| DE (1) | DE69735581T2 (https=) |
| DK (1) | DK0932388T5 (https=) |
| ES (1) | ES2262174T3 (https=) |
| PT (1) | PT932388E (https=) |
| WO (1) | WO1998014168A2 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440457B1 (en) | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| ES2262174T3 (es) * | 1996-09-30 | 2006-11-16 | Alza Corporation | Forma de dosificacion y procedimiento de administracion de medicamentos. |
| US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| US6962997B1 (en) | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
| PT1083879E (pt) * | 1998-06-03 | 2005-01-31 | Alza Corp | Metodos e dispositivos para proporcionar uma terapia de drogas prolongada |
| AU2012232984B2 (en) * | 1998-06-03 | 2015-10-29 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| KR100827254B1 (ko) * | 1998-06-03 | 2008-05-07 | 알자 코포레이션 | 연장된 약물 치료를 제공하기 위한 방법 및 장치 |
| AU2004200938B2 (en) * | 1998-06-03 | 2006-09-14 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
| EP1126826B3 (en) | 1998-11-02 | 2019-05-15 | Alkermes Pharma Ireland Limited | Multiparticulate modified release composition of methylphenidate |
| US6673367B1 (en) * | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
| US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| US7083808B2 (en) | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| AU764453B2 (en) | 1999-10-29 | 2003-08-21 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| MXPA03003895A (es) | 2000-10-30 | 2003-07-28 | Euro Celtique Sa | Formulaciones de hidrocodona de liberacion controlada. |
| US7300668B2 (en) | 2001-10-29 | 2007-11-27 | Massachusetts Institute Of Technology | System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing |
| JP2010229140A (ja) * | 2002-02-22 | 2010-10-14 | Shire Llc | 活性物質送達系及び活性物質を保護し投与する方法 |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
| JP2008509144A (ja) * | 2004-08-04 | 2008-03-27 | アルザ・コーポレーシヨン | 上昇するゼロ次放出パターンを示す持続薬剤放出組成物、そのような組成物を製造する方法 |
| DK2036546T3 (en) | 2004-08-23 | 2018-12-17 | Pejo Iserlohn Heilmittel Und Diaet Gmbh & Co Kg | Psychostimulants containing a pharmaceutical composition |
| US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
| CN102488652B (zh) | 2006-03-16 | 2014-06-18 | 特瑞斯制药股份有限公司 | 含有药物-离子交换树脂复合物的经修饰释放的制剂 |
| US8846100B2 (en) | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
| EP1920768A1 (en) | 2006-11-10 | 2008-05-14 | Abbott GmbH & Co. KG | Solid dosage form with a film containing an active substance, as well as its method of production |
| US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
| US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
| DK3272342T3 (da) | 2011-03-23 | 2021-06-07 | Ironshore Pharmaceuticals & Dev Inc | Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse |
| US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| EP2994112A1 (en) | 2013-03-29 | 2016-03-16 | Wockhardt Limited | Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof |
| DE102013014417A1 (de) | 2013-08-29 | 2015-03-05 | Klinipharm Gmbh | Schwammkollagen umfassende Zubereitungen mit definiertem in vivo-Freisetzungsprofil vor allem im Colon, deren Herstellung und Verwendung |
| WO2015188092A1 (en) * | 2014-06-06 | 2015-12-10 | Rhodes Pharmaceuticals, L.P. | Methods for treating attention deficit hyperactivity disorder with methylphenidate |
| CA2902911C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2738303A (en) * | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
| US3400197A (en) * | 1965-01-26 | 1968-09-03 | Robins Co Inc A H | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules |
| US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| US4304591A (en) * | 1978-01-25 | 1981-12-08 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides |
| EP0094123A3 (en) * | 1982-05-06 | 1984-07-25 | THE PROCTER & GAMBLE COMPANY | Therapeutic granules |
| EP0212747B1 (en) * | 1985-08-16 | 1991-04-10 | The Procter & Gamble Company | Drug particles having constant release and immediate release |
| LU86077A1 (fr) * | 1985-09-18 | 1987-04-02 | Pharlyse Sa | Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques |
| DE3822095A1 (de) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
| SE509029C2 (sv) * | 1988-08-16 | 1998-11-30 | Ss Pharmaceutical Co | Långtidsverkande diklofenak-natriumpreparat |
| US4927639A (en) * | 1989-02-02 | 1990-05-22 | Warner-Lambert Company | Modified release gemfibrozil composition |
| FI93924C (fi) * | 1991-09-17 | 1995-06-26 | Martti Lauri Antero Marvola | Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi |
| US5593694A (en) * | 1991-10-04 | 1997-01-14 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained release tablet |
| ES2194210T3 (es) * | 1996-08-16 | 2003-11-16 | Alza Corp | Forma de dosificacion para suministrar una dosis ascendente de farmaco. |
| ES2262174T3 (es) * | 1996-09-30 | 2006-11-16 | Alza Corporation | Forma de dosificacion y procedimiento de administracion de medicamentos. |
-
1997
- 1997-09-16 ES ES97910713T patent/ES2262174T3/es not_active Expired - Lifetime
- 1997-09-16 AT AT97910713T patent/ATE321529T1/de active
- 1997-09-16 CA CA002264852A patent/CA2264852C/en not_active Expired - Lifetime
- 1997-09-16 AU AU48014/97A patent/AU4801497A/en not_active Abandoned
- 1997-09-16 EP EP97910713A patent/EP0932388B1/en not_active Expired - Lifetime
- 1997-09-16 DE DE69735581T patent/DE69735581T2/de not_active Expired - Lifetime
- 1997-09-16 JP JP51658798A patent/JP4714313B2/ja not_active Expired - Lifetime
- 1997-09-16 DK DK97910713.3T patent/DK0932388T5/da active
- 1997-09-16 CN CN97198342A patent/CN1231603A/zh active Pending
- 1997-09-16 PT PT97910713T patent/PT932388E/pt unknown
- 1997-09-16 WO PCT/US1997/016599 patent/WO1998014168A2/en not_active Ceased
-
2010
- 2010-05-12 JP JP2010110166A patent/JP5697893B2/ja not_active Expired - Lifetime
-
2013
- 2013-10-11 JP JP2013213661A patent/JP2014028854A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PT932388E (pt) | 2006-07-31 |
| CA2264852A1 (en) | 1998-04-09 |
| DE69735581T2 (de) | 2007-01-25 |
| HK1127997A1 (en) | 2009-10-16 |
| DK0932388T5 (da) | 2011-06-27 |
| JP4714313B2 (ja) | 2011-06-29 |
| DK0932388T3 (da) | 2006-07-17 |
| AU4801497A (en) | 1998-04-24 |
| JP2014028854A (ja) | 2014-02-13 |
| JP5697893B2 (ja) | 2015-04-08 |
| ATE321529T1 (de) | 2006-04-15 |
| JP2001501223A (ja) | 2001-01-30 |
| DE69735581D1 (de) | 2006-05-18 |
| EP0932388B1 (en) | 2006-03-29 |
| CA2264852C (en) | 2005-11-01 |
| CN1231603A (zh) | 1999-10-13 |
| WO1998014168A3 (en) | 1998-07-30 |
| JP2010195822A (ja) | 2010-09-09 |
| EP0932388A2 (en) | 1999-08-04 |
| WO1998014168A2 (en) | 1998-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2262174T3 (es) | Forma de dosificacion y procedimiento de administracion de medicamentos. | |
| US20050031688A1 (en) | Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration | |
| US20230157981A1 (en) | Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder | |
| US20200306227A1 (en) | Melatonin mini-tablets and method of manufacturing the same | |
| AU2010282660A1 (en) | Methods for iontophoretically treating nausea and migraine | |
| Bensimon et al. | Antagonism by modafinil of the psychomotor and cognitive impairment induced by sleep-deprivation in 12 healthy volunteers | |
| KR20080028480A (ko) | 티자니딘 조성물 및 이 조성물을 사용하는 치료 방법 | |
| Crowley et al. | Bedtime flurazepam and the human circadian rhythm of spontaneous motility | |
| Keele | The assay of analgesic drugs on man | |
| US10849856B2 (en) | Melatonin mini-tablets and method of manufacturing the same | |
| CA2515884C (en) | Dosage form and method for administering drug | |
| EP1690531A2 (en) | Dosage form and method for administering drug | |
| Harris | Hippocampal Oxygen Dynamics During and Following Febrile Seizures | |
| HK40120004A (en) | Melatonin mini-tablets and method of manufacturing the same | |
| Gottfries | Pharmacological treatment of sleep disorders | |
| EP2905021A1 (en) | Combination for the prophylaxis and treatment of behavioural, mental and cognitive disorders | |
| HK1127997B (en) | Dosage form and method for administering drug | |
| Holloway | Reliability of disposable intraoperative facial nerve stimulators: Randal D, Webster D, Hunsaker D. Laryngoscope 107: 192, 1997 | |
| Machleidt et al. | Anxiety processes in the EEG | |
| Salinas et al. | Prescribing nicotine substitutes for tobacco cessation: Considerations and contraindications | |
| Nakajima | Basic study of cancer chemotherapy with magnetoliposomes containing CDDP. 1: Preparation of magnetoliposomes and their effects on cultured tumor cells: Jinbu Y, Akasaka Y, Ito H, et al. Jpn J Oral Maxillofac Surg 43: 55, 1997 | |
| Prior | A double blind placebo-controlled evaluation of oral zolpidem prior to intravenous midazolam sedation for ambulatory oral surgery | |
| BHASKAR et al. | IRREVERSIBLE DYSKINESIAS FOLLOWING PHENOTHIAZINE THERAPY |